Aptorum GroupAPM
Market Cap: 19.9M
About: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Employees: 3
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
433% more capital invested
Capital invested by funds: $104K [Q4 2023] → $553K (+$449K) [Q1 2024]
200% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 0
67% more funds holding
Funds holding: 3 [Q4 2023] → 5 (+2) [Q1 2024]
0.49% more ownership
Funds ownership: 1.49% [Q4 2023] → 1.98% (+0.49%) [Q1 2024]
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for APM.